- Home
- PTGX vs LNTH Comparison
PTGX vs LNTH Comparison
Compare PTGX & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- LNTH
- Stock Information
- Founded
- PTGX 2006
- LNTH 1956
- Country
- PTGX United States
- LNTH United States
- Employees
- PTGX N/A
- LNTH N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PTGX Health Care
- LNTH Health Care
- Exchange
- PTGX Nasdaq
- LNTH Nasdaq
- Market Cap
- PTGX 5.0B
- LNTH 3.8B
- IPO Year
- PTGX 2016
- LNTH 2015
- Fundamental
- Price
- PTGX $84.63
- LNTH $53.45
- Analyst Decision
- PTGX Strong Buy
- LNTH Buy
- Analyst Count
- PTGX 9
- LNTH 6
- Target Price
- PTGX $86.44
- LNTH $74.17
- AVG Volume (30 Days)
- PTGX 938.5K
- LNTH 1.3M
- Earning Date
- PTGX 11-06-2025
- LNTH 11-06-2025
- Dividend Yield
- PTGX N/A
- LNTH N/A
- EPS Growth
- PTGX N/A
- LNTH N/A
- EPS
- PTGX 0.72
- LNTH 2.39
- Revenue
- PTGX $209,217,000.00
- LNTH $1,525,933,000.00
- Revenue This Year
- PTGX N/A
- LNTH N/A
- Revenue Next Year
- PTGX $140.23
- LNTH $1.98
- P/E Ratio
- PTGX $117.81
- LNTH $22.20
- Revenue Growth
- PTGX N/A
- LNTH 1.95
- 52 Week Low
- PTGX $33.31
- LNTH $47.25
- 52 Week High
- PTGX $93.25
- LNTH $111.29
- Technical
- Relative Strength Index (RSI)
- PTGX 68.10
- LNTH 45.58
- Support Level
- PTGX $76.70
- LNTH $50.16
- Resistance Level
- PTGX $86.90
- LNTH $55.55
- Average True Range (ATR)
- PTGX 3.00
- LNTH 2.71
- MACD
- PTGX 0.40
- LNTH -0.41
- Stochastic Oscillator
- PTGX 84.27
- LNTH 28.09
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.